Physician profile
Jay I Stern
NPI 1598952160
$1,732.59
in general payments reported to CMS, 2019-2025
21 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.72 · 2020: $28.54 · 2023: $534 · 2024: $825 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439.81 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $253.22 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $169.16 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $167.04 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $108.39 | 2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.87 | 2023-2025 | Jardiance |
| Pfizer INC. | $71.75 | 2023-2025 | |
| Exact Sciences Corporation | $65.76 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $59.68 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $40.74 | 2019-2024 | Krystexxa |
| Phadia US INC. | $37.23 | 2023-2024 | Immunocap |
| Cranial Technologies, INC | $37.23 | 2025 | Doc Band |
| Seqirus USA INC | $32.92 | 2019-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biogen, INC. | $27.50 | 2024 | Spinraza |
| Astellas Pharma US INC | $26.18 | 2024 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.42 | 2024 | Gemtesa |
| Mylan Specialty L.P. | $19.24 | 2023 | Yupelri |
| Boston Scientific Corporation | $17.52 | 2025 | Bodyguardian |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.40 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $13.65 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.